C4 Therapeutics (CCCC) Interest Coverage Ratio (2019 - 2026)
C4 Therapeutics' (CCCC) quarterly Interest Coverage Ratio came in at 11.99 in Q1 2026, up 7.52% year-on-year from 11.15 in Q1 2025, and up 96.94% quarter-over-quarter from 392.29 in Q4 2025.
C4 Therapeutics (CCCC) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
C4 Therapeutics' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 11.99 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 7.52% year-over-year to 11.99 in Q1 2026; TTM through Mar 2026 was 837.08, a 5566.64% decrease from a year earlier, with the FY2025 full-year figure at 0.57, up 17.91% from the prior year.
- Interest Coverage Ratio grew to 11.99 in Q1 2026 per CCCC's latest filing, from 392.29 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 11.07 in Q4 2022 and bottomed at 3823.56 in Q3 2025.
- The 5-year median for Interest Coverage Ratio is 14.6 (2023), against an average of 313.31.
- Across the five-year window, Interest Coverage Ratio soared 117.27% in 2022 and sank 9267.97% in 2023, its largest moves.
- Year by year, Interest Coverage Ratio stood at 11.07 in 2022, then slumped by 37.75% to 6.89 in 2023, then retreated by 17.27% to 5.7 in 2024, then plunged by 6980.57% to 392.29 in 2025, then jumped by 96.94% to 11.99 in 2026.
- Per Business Quant, the three latest CCCC Interest Coverage Ratio figures stand at 11.99 (Q1 2026), 392.29 (Q4 2025), and 3823.56 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | -11.99 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.99 |
| Dec 31, 2025 | -392.29 |
| Sep 30, 2025 | -3,823.56 |
| Jun 30, 2025 | -351.86 |
| Mar 31, 2025 | -12.97 |
| Dec 31, 2024 | 5.70 |
| Sep 30, 2024 | -627.64 |
| Jun 30, 2024 | -47.86 |
| Mar 31, 2024 | -14.75 |
| Dec 31, 2023 | 6.89 |
| Sep 30, 2023 | -30.52 |
| Jun 30, 2023 | -20.94 |
| Mar 31, 2023 | -14.60 |
| Dec 31, 2022 | 11.07 |
| Sep 30, 2022 | -0.33 |
| Jun 30, 2022 | -0.27 |
| Mar 31, 2022 | -0.30 |
| Dec 31, 2021 | -64.10 |
| Sep 30, 2021 | -1.46 |
| Jun 30, 2021 | -4.57 |